Inventor · disambiguated record
Lianfeng Huang
Also filed as: HUANG LIANFENG
32 granted patents·7 pending applications·76 citations·filing 2013–2025
95Inventor score
Top patents by PatentIndex Score
39 records- 0197US9365524B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2015·Granted Jun 14, 2016·22 cites·36 claims
- 0296US9814713B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2016·Granted Nov 14, 2017·14 cites·21 claims
- 0392US10882867B2Forms and compositions of a MK2 inhibitorCELGENE CAR LLC·Filed 2018·Granted Jan 5, 2021·8 cites·23 claims
- 0491US9796685B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2015·Granted Oct 24, 2017·14 cites·7 claims
- 0590US11434200B2Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereofNOVARTIS AG·Filed 2020·Granted Sep 6, 2022·2 cites·24 claims
- 0686US11053199B2Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted Jul 6, 2021·2 cites·15 claims
- 0785US11680046B2Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereofCELGENE CORP·Filed 2021·Granted Jun 20, 2023·1 cites·12 claims
- 0884US10131639B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2017·Granted Nov 20, 2018·4 cites·18 claims
- 0983US11629153B2Forms and compositions of a MK2 inhibitorCELGENE CAR LLC·Filed 2020·Granted Apr 18, 2023·1 cites·33 claims
- 1082US11629124B2Solid forms comprising an oxime ether compound, compositions and methods of use thereofNOVARTIS AG·Filed 2020·Granted Apr 18, 2023·1 cites·10 claims
- 1182US2025340536A1Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2025·Application pending·0 cites
- 1281US11013723B1Solid forms of a thiazolidinone compound, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted May 25, 2021·2 cites·30 claims
- 1380US10047090B2Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted Aug 14, 2018·3 cites·4 claims
- 1477US12410133B2Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereofCELGENE CORP·Filed 2023·Granted Sep 9, 2025·0 cites·16 claims
- 1574US12049446B2Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereofNOVARTIS AG·Filed 2022·Granted Jul 30, 2024·0 cites·13 claims
- 1674US10590089B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2018·Granted Mar 17, 2020·1 cites·48 claims
- 1772US12391672B2Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2022·Granted Aug 19, 2025·0 cites·7 claims
- 1872US10543214B2Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2018·Granted Jan 28, 2020·0 cites·62 claims
- 1971US11701362B2Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2020·Granted Jul 18, 2023·0 cites·25 claims
- 2070US10005760B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2015·Granted Jun 26, 2018·1 cites·21 claims
- 2170US2023219887A1Solid forms comprising an oxime ether compound, compositions and methods of use thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 2269US10898488B2Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2020·Granted Jan 26, 2021·0 cites·33 claims
- 2368US2015051157A1Romidepsin formulations and uses thereofCELGENE CORP·Filed 2014·Application pending·0 cites
- 2467US10653697B2Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamideCELGENE CORP·Filed 2019·Granted May 19, 2020·0 cites·39 claims
- 2567US9795650B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2016·Granted Oct 24, 2017·0 cites·12 claims
- 2667US9782451B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2016·Granted Oct 10, 2017·0 cites·12 claims
- 2765US9463215B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2015·Granted Oct 11, 2016·0 cites·6 claims
- 2864US2015182584A1Romidepsin formulations and uses thereofCELGENE CORP·Filed 2014·Application pending·0 cites
- 2962US11370777B2Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2020·Granted Jun 28, 2022·0 cites·28 claims
- 3060US11958805B2Solid forms comprising an oxime ether compound, compositions and methods of use thereofNOVARTIS AG·Filed 2020·Granted Apr 16, 2024·0 cites·38 claims
- 3160US9468664B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2015·Granted Oct 18, 2016·0 cites·6 claims
- 3260US2013184225A1Romidepsin formulations and uses thereofHUANG LIANFENG·Filed 2013·Application pending·0 cites
- 3359US10202364B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 12, 2019·0 cites·16 claims
- 3459US2016367625A1Romidepsin formulations and uses thereofCELGENE CORP·Filed 2016·Application pending·0 cites
- 3558US11578056B2Solid forms comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the sameCELGENE CORP·Filed 2020·Granted Feb 14, 2023·0 cites·34 claims
- 3657US11014897B1Solid forms comprising a thiazolidinone compound, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted May 25, 2021·0 cites·20 claims
- 3754US10513519B2Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their useSIGNAL PHARM LLC·Filed 2018·Granted Dec 24, 2019·0 cites·30 claims
- 3851US11186556B1Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted Nov 30, 2021·0 cites·24 claims
- 3946US2018258064A1Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lianfeng Huang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →